{"entity":{"id":"nct05023980","kind":"trial","name":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","aka":["BRUIN CLL-313"],"tldr":"A phase 3 trial of Pirtobrutinib, Bendamustine and Rituximab in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., active and no longer recruiting.","summary":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) is a phase 3 interventional study registered as NCT05023980 by Loxo Oncology, Inc., with 309 participants enrolled, started 2021-09-23 and due to reach its primary completion in 2025-07-11. Interventions recorded: Pirtobrutinib, Bendamustine and Rituximab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05023980","url":"https://clinicaltrials.gov/study/NCT05023980"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll","cll-treatment-naive"],"sections":[],"technologies":["cytotoxic-chemotherapy","kinase-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["pirtobrutinib","bendamustine","rituximab"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05023980","phase":"3","setting":"A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","sponsor":"Loxo Oncology, Inc.","participation":[{"nct":"NCT05023980","source":"https://clinicaltrials.gov/study/NCT05023980","fetchedAt":"2026-10-07T16:53:32.717Z","studySha256":"f4725eb7ce570b63927b2275bf38db7ef3ebf9ed34962842dfe4c9510ee082ee","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"Loxo Oncology, Inc.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":282,"enrolmentType":"ACTUAL","siteCount":108,"recruitingSiteCount":0,"countries":["Australia","Austria","Brazil","Bulgaria","China","Czechia","France","Hungary","Italy","Japan","New Zealand","Poland","Portugal","Romania","Russia","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2021-09-23","startedType":"actual","enrolled":309,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05023980/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/"},{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}